Drug Trial News

RSS

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

12 Jul 2011

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.

8 Jul 2011

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.

8 Jul 2011

Collaborative research discovers broadly acting antibody against influenza viruses

Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical company Crucell. They describe an antibody that, in animal tests, can prevent or cure infections with a broad variety of influenza viruses, including seasonal and potentially pandemic strains.

8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Drug Trial News

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Combination therapy shows promise against HER2-positive metastatic breast cancer

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Collaborative research discovers broadly acting antibody against influenza viruses

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News